• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Inflamax introduces ePDAT for real-time PRO data collection


New tablet facilitates and standardizes patient reported outcomes data collection.

Toronto, Ontario-Inflamax Research has introduced its electronic Patient Data Acquisition Tablet (ePDAT) which not only facilitates but standardizes patient reported outcomes (PRO) data collection across multi-center clinical trials.

The validated ePDAT system provides a graphical user interface via a touchscreen tablet computer designed to provide an improved user experience. The system was designed to enhance user experience, accuracy, and quality while ensuring compliance with FDA and EMA requirements for validated ePRO data collection tools. ePDAT is fully CFR21 part 11 compliant.

PRO data can be collected by on-screen questionnaires, visual analog scales (VAS), response time, coordination tasks, high-resolution image capture, and evaluator interview via video conferencing.

Software architecture allows patient data to be recorded in real-time via the tablet’s cellular wireless connection to the company’s secure database servers. Data is also stored locally on the tablet as backup. 

Related Videos
Charles Leclercq, CEO of ARxVision, details the new ARx AI headset and its uses
© 2024 MJH Life Sciences

All rights reserved.